Compare PEB & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | STOK |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | PEB | STOK |
|---|---|---|
| Price | $18.97 | $31.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $13.30 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 2.4M | 475.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $9.30 | $11.17 |
| 52 Week High | $19.60 | $40.22 |
| Indicator | PEB | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 73.73 | 53.24 |
| Support Level | $11.54 | $30.34 |
| Resistance Level | N/A | $35.11 |
| Average True Range (ATR) | 0.58 | 1.46 |
| MACD | 0.19 | 0.24 |
| Stochastic Oscillator | 84.42 | 86.66 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.